Arcutis Biotherapeutics (ARQT) Stock Price, News & Analysis

-0.20 (-2.24%)
(As of 04/23/2024 ET)
Today's Range
50-Day Range
52-Week Range
1.60 million shs
Average Volume
4.69 million shs
Market Capitalization
$846.12 million
P/E Ratio
Dividend Yield
Price Target

Arcutis Biotherapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
203.8% Upside
$26.56 Price Target
Short Interest
19.89% of Shares Sold Short
Dividend Strength
News Sentiment
0.58mentions of Arcutis Biotherapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$41,811 Sold Last Quarter
Proj. Earnings Growth
From ($2.49) to ($1.77) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.63 out of 5 stars

Medical Sector

639th out of 909 stocks

Pharmaceutical Preparations Industry

290th out of 425 stocks

ARQT stock logo

About Arcutis Biotherapeutics Stock (NASDAQ:ARQT)

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

ARQT Stock Price History

ARQT Stock News Headlines

Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 8.8%
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Arcutis Biotherapeutics Inc Ordinary Shares ARQT
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Arcutis Biotherapeutics appoints CFO
ARQT May 2024 10.000 call
ATHA Apr 2024 2.500 put
ARQT Apr 2024 12.500 call
ARQT Apr 2024 5.000 call
ARQT Apr 2024 2.500 call
See More Headlines
Receive ARQT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcutis Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
8 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$59.61 million
Book Value
$0.94 per share


Free Float
Market Cap
$866.45 million

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Todd Franklin Watanabe M.A.Mr. Todd Franklin Watanabe M.A. (Age 56)
    President, CEO & Director
    Comp: $1.01M
  • Dr. Bhaskar Chaudhuri Ph.D. (Age 69)
    Co-Founder & Independent Director
    Comp: $59.67k
  • Mr. Masaru Matsuda Esq. (Age 53)
    J.D., Senior VP, General Counsel & Corporate Secretary
    Comp: $626.22k
  • Dr. Patrick E. Burnett M.D. (Age 52)
    Ph.D., Senior VP & Chief Medical Officer
    Comp: $689.95k
  • Mr. John W. Smither CPA (Age 71)
    Chief Financial Officer
    Comp: $410.75k
  • Mr. Rajvir Madan
    Chief Digital & Technology Officer
  • Ms. Latha Vairavan
    Vice President of Finance & Investor Relations
  • Ms. Courtney Barton (Age 41)
    VP and Chief Compliance Officer & Privacy Officer
  • Ms. Amanda Sheldon
    Head of Corporate Communications
  • Ms. Ayisha Jeter
    Head of Marketing & Market Access

ARQT Stock Analysis - Frequently Asked Questions

Should I buy or sell Arcutis Biotherapeutics stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcutis Biotherapeutics in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ARQT shares.
View ARQT analyst ratings
or view top-rated stocks.

What is Arcutis Biotherapeutics' stock price target for 2024?

8 Wall Street analysts have issued 12-month price objectives for Arcutis Biotherapeutics' stock. Their ARQT share price targets range from $8.00 to $50.00. On average, they predict the company's share price to reach $26.56 in the next year. This suggests a possible upside of 203.8% from the stock's current price.
View analysts price targets for ARQT
or view top-rated stocks among Wall Street analysts.

How have ARQT shares performed in 2024?

Arcutis Biotherapeutics' stock was trading at $3.23 at the beginning of 2024. Since then, ARQT stock has increased by 170.6% and is now trading at $8.74.
View the best growth stocks for 2024 here

Are investors shorting Arcutis Biotherapeutics?

Arcutis Biotherapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 19,260,000 shares, an increase of 28.5% from the March 15th total of 14,990,000 shares. Based on an average trading volume of 4,760,000 shares, the short-interest ratio is currently 4.0 days.
View Arcutis Biotherapeutics' Short Interest

When is Arcutis Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our ARQT earnings forecast

How were Arcutis Biotherapeutics' earnings last quarter?

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) released its quarterly earnings data on Tuesday, February, 27th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.64) by $0.08. The firm had revenue of $13.53 million for the quarter, compared to analysts' expectations of $11.78 million. Arcutis Biotherapeutics had a negative net margin of 439.79% and a negative trailing twelve-month return on equity of 294.85%. During the same period last year, the business earned ($1.18) earnings per share.

What ETFs hold Arcutis Biotherapeutics' stock?

ETFs with the largest weight of Arcutis Biotherapeutics (NASDAQ:ARQT) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH), SPDR S&P Biotech ETF (XBI) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).Invesco DWA SmallCap Momentum ETF (DWAS).

What other stocks do shareholders of Arcutis Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcutis Biotherapeutics investors own include Black Diamond Therapeutics (BDTX), Pfizer (PFE), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD), Applied Therapeutics (APLT), Aptinyx (APTX), BioNTech (BNTX), ServiceNow (NOW), Qualys (QLYS) and AbbVie (ABBV).

When did Arcutis Biotherapeutics IPO?

Arcutis Biotherapeutics (ARQT) raised $125 million in an initial public offering (IPO) on Friday, January 31st 2020. The company issued 7,800,000 shares at $15.00-$17.00 per share. Goldman Sachs, Cowen and Guggenheim Securities acted as the underwriters for the IPO and Cantor was co-manager.

Who are Arcutis Biotherapeutics' major shareholders?

Arcutis Biotherapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include AMI Asset Management Corp (0.36%), Fishman Jay A Ltd. MI (0.23%), Los Angeles Capital Management LLC (0.15%) and Hennion & Walsh Asset Management Inc. (0.05%). Insiders that own company stock include Bhaskar Chaudhuri, David W Osborne, Howard G Welgus, Life Sciences Viii L Frazier, Masaru Matsuda, Orbimed Advisors Llc, Patricia A Turney, Patrick Burnett, Scott L Burrows and Todd Franklin Watanabe.
View institutional ownership trends

How do I buy shares of Arcutis Biotherapeutics?

Shares of ARQT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ARQT) was last updated on 4/23/2024 by Staff

From Our Partners